Business UpdateJun 11, 2026, 07:06 AM
Purple Biotech Presents Positive Preclinical Data for IM1240
AI Summary
Purple Biotech Ltd. presented new preclinical data for its lead CAPTN-3 program, IM1240, at the European Association for Cancer Research (EACR) 2026 Annual Congress. The data highlights IM1240's anti-tumor activity in resistant cancer types and a favorable safety and pharmacokinetic profile validated in non-human primates. These results support the planned advancement of IM1240 towards a first-in-human clinical study in 2027.
Key Highlights
- IM1240 demonstrated anti-tumor activity in PD-1- and chemotherapy-resistant patient-derived tumor samples.
- A non-GLP toxicology study in NHPs validated the CAPTN-3 masking strategy for IM1240.
- IM1240 showed an 8-fold longer half-life and 16-fold greater exposure compared to the non-capped variant in NHP toxicology study.
- IM1240 induced minimal IL-6 and TNF-α at 10 mg/kg, while the non-capped variant induced robust cytokine release at 0.03 mg/kg.
- IM1240 demonstrated ~14-fold slower clearance than active non-capped IM1222 in NHPs.
- Data supports the planned advancement of IM1240 toward a first-in-human clinical study in 2027.
Price Impact
More from PPBT